Table 2.

Comparison of the total QOL scores using SF-36 before and after treatment.

	Age	Baseline	Week 50	Clinical study
Over 20 years old
VL-1	26y	247.4	267.8	307.5 (198th week)
VL-2	25y	392	423.4	429.4 (186th week)
VL-5	22y	371	385.8	449.6 (150th week)
Average		336.8	359 (P = .045 vs. baseline)	395.5 (P = .038 vs. baseline) (P = .161 vs. week 50)
Under 20 years old
VL-3	6y	381.3	415.5	362.7 (174th week)
VL-4	6y	271.5	353.5	347.0 (126th week)
CP-1	5y	379.7	400.2	388.2 (162nd week)
Average		344.2	389.7 (P = .134 vs. baseline)	366.0 (P = .517 vs. baseline) (P = .245 vs. week 50)
Total Average		340.5	374.4 (P = .020 vs. baseline)	380.7 (P = .053 vs. baseline; P = .719 vs. week 50)

Elevation of the QOL score indicates improvement in QOL among total cases, and cases older or younger than 20 years old.